Profile data is unavailable for this security.
About the company
Euroapi SAS is a France-based company. The Company is engaged in the development, manufacture and supply of active-ingredient solutions to its healthcare partners. It offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates (morphine, codeine, thebaine, etc.), analgesics, etc. The Company also provides technologies and develops molecules through it’s Contract Development and Manufacturing Organization (CDMO). It’s CDMO services include Tides, Prostaglandins, Particle Engineering, Microbial Fermentation, Small Molecules Synthesis, Steroids and Hormones and Opiates & Controlled Substances. It has production sites located in France, the United Kingdom, Germany, Italy and Hungary.
- Revenue in EUR (TTM)971.30m
- Net income in EUR-287.30m
- Incorporated2020
- Employees3.67k
- LocationEuroapi SA15, rue TraversierePARIS 75012FranceFRA
- Phone+33 189206200
- Websitehttps://www.euroapi.com/en
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Celon Pharma SA | 48.27m | -10.47m | 322.37m | 566.00 | -- | 2.89 | 169.59 | 6.68 | -0.8908 | -0.8908 | 4.11 | 9.00 | 0.3592 | 2.21 | 5.21 | 400,898.70 | -7.79 | -2.24 | -9.03 | -2.57 | 70.12 | 70.71 | -21.69 | -7.79 | 2.27 | -64.27 | 0.0321 | -- | 11.29 | 11.57 | 28.40 | -- | -13.42 | -19.73 |
| Cutia Therapeutics | 26.20m | -69.09m | 324.37m | 360.00 | -- | 1.98 | -- | 12.38 | -1.85 | -1.85 | 0.7018 | 4.19 | 0.1206 | 2.31 | 6.93 | 716,808.00 | -31.81 | -- | -35.82 | -- | 50.33 | -- | -263.68 | -- | 4.82 | -- | 0.1818 | -- | 1,110.83 | -- | -253.30 | -- | -- | -- |
| Euroapi SA | 971.30m | -287.30m | 326.73m | 3.67k | -- | 0.3661 | -- | 0.3364 | -3.04 | -3.04 | 10.29 | 9.34 | 0.5306 | 1.23 | 4.68 | 264,731.50 | -15.69 | -- | -23.68 | -- | 17.04 | -- | -29.58 | -- | 0.7027 | -- | 0.3464 | -- | 3.87 | -- | -1,164.67 | -- | -- | -- |
| Standard Chem & Pharm Co Ltd | 196.71m | 24.85m | 334.84m | 1.13k | 13.48 | 1.93 | 7.13 | 1.70 | 4.74 | 4.74 | 37.50 | 33.05 | 0.6066 | 2.39 | 6.00 | -- | 10.98 | 9.68 | 20.02 | 17.61 | 43.81 | 43.75 | 18.10 | 17.02 | 1.93 | -- | 0.0795 | 60.34 | 6.64 | 11.80 | 2.39 | 17.40 | 29.97 | 12.47 |
| Medios AG | 1.84bn | 12.88m | 335.66m | 1.00k | 24.71 | 0.6614 | 8.42 | 0.1823 | 0.5326 | 0.5326 | 76.07 | 19.90 | 2.39 | 23.11 | 12.28 | 3,576,214.00 | 1.67 | 3.40 | 2.36 | 4.07 | 7.19 | 6.05 | 0.699 | 1.01 | 0.7551 | 5.97 | 0.3174 | 0.00 | 10.80 | 40.34 | 2.62 | 34.17 | -7.11 | -- |
| Novoprotein Scientific Inc | 17.75m | -2.81m | 337.69m | 579.00 | -- | 1.19 | -- | 19.02 | -0.3031 | -0.3031 | 1.92 | 30.57 | 0.0592 | 0.5833 | 1.96 | 232,406.80 | -0.937 | -- | -0.959 | -- | 61.17 | -- | -15.82 | -- | 34.60 | -- | 0.0323 | -- | -42.09 | -- | -85.84 | -- | -- | -- |
| Ginwa Enterprise Group Inc | 76.71m | -2.05m | 338.27m | 553.00 | -- | 1.69 | -- | 4.41 | -0.0382 | -0.0382 | 1.58 | 4.07 | 0.2968 | 4.81 | 5.28 | 1,051,591.00 | -0.7916 | 0.3641 | -0.9515 | 0.4141 | 76.18 | 73.64 | -2.67 | 1.15 | 2.19 | 0.196 | 0.0431 | 124.25 | -2.41 | -5.37 | -228.19 | -- | 61.66 | -- |
| Amylyx Pharmaceuticals Inc | 187.58m | -247.71m | 339.65m | 384.00 | -- | 1.81 | -- | 1.81 | -3.82 | -3.82 | 2.87 | 2.86 | 0.5479 | 2.56 | 12.64 | 511,679.70 | -72.35 | -- | -84.00 | -- | 78.88 | -- | -132.05 | -- | 4.55 | -- | 0.00 | -- | 1,612.94 | -- | 124.84 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Euroapi SA's reporting currency: Euro EUR
22.75%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Kopernik Global Investors LLCas of 12 Mar 2024 | 4.98m | 5.21% |
| MAK Capital One LLCas of 08 Feb 2024 | 4.77m | 4.99% |
| CDC Croissance SAas of 26 Jan 2024 | 4.75m | 4.97% |
| Brandes Investment Partners LPas of 14 Nov 2024 | 2.34m | 2.45% |
| Schroder Investment Management Ltd.as of 31 Jul 2024 | 1.61m | 1.68% |
| Niche Asset Management Ltd.as of 30 Jun 2024 | 1.21m | 1.26% |
| EdenTree Investment Management Ltd.as of 30 Jun 2024 | 700.00k | 0.73% |
| DNCA Finance SAas of 29 Dec 2023 | 643.71k | 0.67% |
| Zenito Oyas of 30 Sep 2024 | 400.00k | 0.42% |
| Mercer Global Investments Europe Ltd.as of 31 Dec 2023 | 357.82k | 0.37% |
More ▼
Data from 17 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
